Reduction of Surgical Site Infection in Cardiac Surgery using a Microbial Sealant-A Controlled Study
In coronary artery bypass patients requiring greater than 2 lengths of saphenous vein for conduit does the application of a cyanoacrylate surgical sealant prior to leg wound incision decrease wound infection rates scored at 1 month when compared to the contralateral leg wound in the same patient.
Ian Gilfillan
100 participants
Jul 14, 2008
Interventional
Conditions
Summary
A trial to see if the use of a cyanoacrylate ("Superglue") sealant applied to the skin prior to the surgical incsion can reduce the incidence of post operative wound infections.
Eligibility
Inclusion Criteria1
- Isolated Coronary Artery bypass patients requiring greater than 2 lengths of saphenous vein conduit.
Exclusion Criteria1
- Peripheral vascular disease, long saphenous vein abnormality, leg skin lesions or ulcers, prior sensitivity to cyanoacrlate, acetone or formaldehyde containg products, non consent.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Application of a cyanoacrylate microbial surgical sealant to the skin surface immediately prior to skin incision for removal of the long saphenous vein for coronary artery bypass surgery. Applied directly from sterile container with sponge applicator. Probable mechanism of action is the fixation of microorganisms within hair follicles and sweat glands, thus reducing quantitatively the contamination of the incision.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12610000743066